

REMARKS

Claims 6-9, 12-23 and 30 were finally rejected in the Office Action of March 25, 2003. Applicants thank the Examiner for withdrawing the previous rejections under 35 U.S.C. §§ 101, 102, and 112, second paragraph.

Applicants request reconsideration of the outstanding rejections in view of the comments set forth herein and in the Amendment And Response Pursuant to 37 C.F.R. § 1.111, filed December 20, 2002, said comments being incorporated by reference in their entirety herein.

Claim Objection

Claim 16 was objected to because “derives” should be –derived–. The basis of this objection is unclear since claim 16 does not recite the term “derives.” Clarification is respectfully requested.

Objections to the Drawings

The Examiner again objects to the drawings for reasons that were supposed to be indicated on an accompanying PTO Form 948. The Examiner indicates that corrected drawings are required and that this objection will not be held in abeyance. However, as the undersigned indicated in a phone message to the Examiner, Applicants are not in receipt of PTO Form 948 and, therefore, are unable to respond to this objection. Applicants thank the Examiner for the return phone call, directing Applicants to note that the PTO Form 948 was not received with the Office Action. Applicants respectfully request clarification from the Examiner with respect to objection.

Rejections under 35 U.S.C. § 112, ¶ 1: Written Description

Claims 6-9, 11-14, and 16-23 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors were in possession of the claimed invention at the time the application was filed. Applicants respectfully traverse this rejection.

Applicants respectfully disagree with the Examiner's assertion that Applicant urges that "teaching *T. fusca* genes is enough." What was asserted and is reiterated is that the instant specification adequately describes the claimed invention and clearly allows persons of ordinary skill in the art to recognize that Applicants invented the claimed subject matter

As pointed out in the previous response, § 112, first paragraph does not require a description of all other DNA molecules encoding cellulases encompassed by the claims. Nor does it require a description of the structural features that distinguish all such nucleic acids from other nucleic acids. At most, the law requires a description of a representative number of species.

The claimed invention is directed to "[a] transgenic plant comprising a nucleic acid encoding a cellulase" and a transgenic seed obtained therefrom, not to "a nucleic acid encoding a cellulase" *per se*. Therefore, the written description needs to be specific enough to lead the skilled artisan to the class of DNA molecules that encode cellulases. *In re Herschler*, 591 F.2d 693, 702 ("claims drawn to the use of known chemical compounds in a manner auxiliary to the invention must have a corresponding written description only so specific as to lead one having ordinary skill in the art to that class of compounds.") Moreover, as the Office has indicated, a proper determination of whether the written description requirement is satisfied necessitates a reading of the disclosure in the light of the knowledge possessed by those of skill in the art at the time of filing. MPEP § 2163 II.A.2.

Applicants reiterate that the specification more than satisfies the written description requirements of § 112, first paragraph. For example, as previously pointed out, the specification teaches *T. fusca* E1, E2, E4, and E5 genes. Specifically, the specification states,

The *T. fusca* genes that encode cellulose-degrading enzymes have been cloned and extensively characterized. (*See, e.g.,* Collmer *et al.* (1983) Bio/Technology 1:594-601, hereby incorporated by reference; Ghangas *et al.* (1988) Appl. Environ. Microbiol. 54:2521-2526, hereby incorporated by reference; and Wilson (1992) Crit. Rev. Biotechnol. 12:45-63, hereby incorporated by reference). In addition, the DNA

sequences of a cellobiohydrolase gene and an endoglucanase gene from *T. fusca* have been determined (Jung *et al.* (1993) Appl. Environ. Microbiol. 59:3032-3043, hereby incorporated by reference); and the DNA sequences of three endoglucanase genes from *T. fusca* have also been determined (Lao *et al.* (1991) J. Bacteriol. 173:3397-3407, hereby incorporated by reference)....

Specification, p. 4, ¶ 1.

Contrary to the Examiner's assertion, while Collmer does describe an endocellulase gene from *Thermomonospora. YX*, the reference also teaches that Whittle et al. cloned a cellulase gene from *Cellulomonas fimi* and that Cornet et al. cloned a thermophilic cellulase gene from *Clostridium Thermocellum*. (See 595, left hand column, third paragraph.)

As Applicants additionally pointed out previously, a variety of other exemplary genes are taught in the specification, including, for example, a *B. subtilis* endoglucanase and a *C. fimi* β -D-glucosidase (Yoo *et al.* (1992) Biotechnol. Lett. 14:77-82), as well as several cellulases that have been expressed from heterologous systems and have been reported in the literature (see Thomas *et al.*, "Initial Approaches to Artificial Cellulase Systems for Conversion of Biomass to Ethanol" in *Enzymatic Degradation of Insoluble Carbohydrates*, J.N. Saddler and M.H. Penner, eds., ACS Symposium Series 618:208-36, 1995, American Chemical Society, Washington, D.C., Table II, pp. 214-216 (enclosed herewith as Exhibit A). As described in the specification, these exemplary cellulases include, but are not limited to, endoglucanases, exoglucanases, and β -D-glucosidases derived from microorganisms such as bacteria and fungi. See Specification, paragraph bridging pp. 14 and 15.

In addition, the specification provides examples that describe, in detail, plants that express *T. fusca* sequences encoding two β -1,4-endoglucanases (*i.e.*, *T. fusca* E1 and E5) as well as a cellobiohydrolase (*i.e.*, *T. fusca* E2). See Specification at, *inter alia*, pp. 39-45 (Examples A1 through A11)

Applicants therefore reiterate that the specification reasonably conveys that Applicants were in possession of the claimed invention at the time the application was

filed. Not only does the specification provide sufficient teaching to clearly lead the skilled artisan to the relevant class of nucleic acids (*i.e.*, those encoding cellulases) to be transformed into a plant in accordance with the claimed invention, but it more than adequately describes a representative number of species within that class (*i.e.*, DNA molecules encoding: endocellulases, such as β -1,4-endoglucanases; exocellulases, such as cellobiohydrolases; and cellobioses, such as 1,4- β -D-glucosidases).

For the reasons set forth above, Applicants submit that the instant application provides sufficient written description support for the claimed invention, *i.e.*, a transgenic plant comprising a nucleic acid encoding a cellulase and a transgenic seed obtained therefrom. The law requires no more. Accordingly, Applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. § 112, first paragraph.

Rejections under 35 U.S.C. § 112, ¶ 1: Enablement

Claims 6-9, 11-14, and 16-23 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly not being enabled by the specification. The Examiner contends that the specification does not reasonably provide enablement for “nucleic acids encoding all cellulases, plants transformed with those cellulases, or non-transformed plants that express cellulases.” Office Action, p. 4. The Examiner further contends that the specification does not enable any person skilled in the art to which it pertains to make and use the invention commensurate in scope with these claims. Applicants again respectfully traverse this rejection.

The Examiner asserts that Applicants’ previous arguments are not persuasive because page 4 of the specification (Collmer et al., Ghanges et al., Wilson, and Lao) teaches *T. fusca* cellulases. Applicants respectfully disagree. As pointed out above the cited references teach a variety of genes encoding cellulases, not just genes from *T. fusca*. For example, Collmer teaches an endocellulase gene from *Thermomonospora*. YX, and also teaches that Whittle et al. cloned a cellulase gene from *Cellulomonas fimi* and that Cornet et al. cloned a thermophilic cellulase gene from *Clostridium Thermocellum*. (See 595, left hand column, third paragraph.)

The Examiner further asserts that it's only Thomas et al. that discusses cellulases from other organisms and that the reference only addresses enzymes. Applicants respectfully direct the Examiner's attention to Table II, pages 214-216 of Thomas et al., which provides a list of genes encoding cellulases from a variety of organisms.

Hence, contrary to the Examiner's allegations, the instant disclosure provides sufficient guidance and direction to enable the practice of the claimed invention without undue experimentation. As discussed above, the specification provides considerable guidance and direction regarding the class of cellulases that may be expressed in a plant in accordance with the claimed invention. In particular, the specification describes various cellulases that have been cloned, characterized, and/or heterologously expressed in bacterial hosts. These described cellulases include endocellulases (*e.g.*, β -1,4-endoglucanases); exocellulases (*e.g.*, cellobiohydrolases); and cellobioses (*e.g.*, 1,4- β -D-glucosidases). See, *e.g.*, Specification, p. 4, ¶¶ 1 and 2; and paragraph bridging pp. 14 and 15 (as quoted above).

The Examiner contends that the specification as well as the cited art, other than Thomas, are limited to teachings of *T. fusca*. For the reasons set forth above, Applicants respectfully disagree.

Applicants submit that the disclosure provides more than a reasonable amount of guidance and direction for using the disclosed means to express a cellulase in a plant. In addition to providing numerous references that disclose various cellulase genes (see, *e.g.*, Specification, pp. 14-15), the specification provides detailed guidance regarding the modification of microbial genes to optimize nuclear expression of those genes in plants. Specification, pp. 15-18. There is also guidance and direction regarding the construction of plant transformation vectors (Specification, pp. 18-21) as well as the construction of plant expression cassettes (Specification, pp. 21-24), including examples of expression cassette construction and a detailed discussion of various plant expressible promoters that may be employed in the practice of the invention (Specification, pp. 24-33). The specification also provides guidance regarding the transformation of both

dicotyledons and monocotyledons (Specification, pp. 33-36), as well as plastid transformation techniques (Specification, pp. 36-38).

Moreover, the specification discloses numerous working examples of various means for expressing cellulase in a plant. There are several examples of the preparation of constructs containing various cellulase coding sequences (*i.e.*, *T. fusca* E1, E2, and E5), each fused either to an inducible or constitutive plant expressible promoter (*i.e.*, tobacco PR-1a or CaMV 35S, respectively) (Examples A1-A6). There are examples of the transformation of various monocot and dicot plants (*i.e.*, tobacco, maize, and wheat) with the disclosed cellulase constructs (Examples A7-A9). There are examples regarding the vacuole-targeted expression of cellulases (Examples B1-B13). There are also examples of chloroplast expression of cellulase genes (Examples C1-C13).

Applicants respectfully submit that the working examples, in conjunction with the remainder of the disclosure, provide sufficient guidance and direction to enable one skilled in the art to practice the claimed invention employing no more than routine experimentation. Specifically, in view of the advanced state of the transformation art as of the filing date of the instant application and the specification's detailed guidance and direction regarding the transformation of plants to achieve the expression of cellulase, a skilled artisan would have been able to transform a plant with any of a variety of known cellulase genes employing no more than routine experimentation.

Applicants respectfully reiterate that "[e]nablement is not precluded by the necessity for some experimentation such as routine screening." *In re Wands*, 858 F.2d 731, 736-737 (Fed. Cir. 1988). In fact, "a considerable amount of experimentation is permissible, if it is merely routine, or if the specification provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed." *Id.* at 737 (internal citation omitted). The instant specification provides such guidance, via general teachings and more detailed examples. Practicing non-exemplified embodiments of the claimed invention would have required the routine preparation of vector constructs, in accordance with the teachings of the disclosure, and limited and systematic routine screening of, for example, plants transformed to express the various

disclosed species within the described genus of cellulase genes. Applicants respectfully submit that, even where required, such efforts do not rise to the level of undue experimentation.

For the foregoing reasons, Applicants respectfully submit that the instant specification, coupled with what was known in the art at the time of filing, would have provided sufficient guidance to enable one of ordinary skill in the art to practice the claimed invention without undue experimentation. Accordingly, the claimed invention is enabled, and Applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. § 112, first paragraph.

Rejection under 35 U.S.C. § 102: Yoshikawa

Claims 6-7 and 17-23 stand rejected under 35 U.S.C. § 102(b) as being anticipated by Yoshikawa *et al.* (1993, *Naturwissenschaften* 80:417-420) (“Yoshikawa”) in light of each of Takeuchi *et al.* (1990, *Plant Physiol.* 93:673-682) (“Takeuchi”) and Melchers *et al.* (1993, *Plant Mol. Biol.* 21:583-593) (“Melchers”).

Applicants traverse this rejection and respectfully submit that the Examiner incorrectly asserts that “the specification (p. 3, lines 14-25) describe β -1,3-endoglucanase as a cellulose degrading enzyme and states that they’re also called endocellulases. The recited text in the specification states refers to β -1,4-endoglucanase, not β -1,3-endoglucanase. As Applicants stated in the previous response, β -1,3-endoglucanase are not cellulases. Thus, the reference fails to teach each and every element of the claimed invention.

Applicants therefore respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. § 102(b).

Rejection under 35 U.S.C. § 102: Borriss

Claims 6-7, 11-13, 18, and 21 stand rejected under 35 U.S.C. § 102(e) as being anticipated by Borriss *et al.*, U.S. Patent No. 5,470,725, filed February 16, 1990 (“Borriss”).

Applicants respectfully reiterate that Borriss does not disclose a “transgenic plant comprising a nucleic acid encoding a cellulase” and a transgenic seed obtained therefrom, as recited in amended Claims 6-7, 12-13, 18, and 21. For example, Borriss does not describe a cellulase. Borriss discloses a (1,3-1,4)- β -glucanase and teaches that “(1,3-1,4)- β -glucanases ... cleave the β -glycosidic linkages in (1,3-1,4)- β -glucans.” Col. 1, lines 15-18. Applicants submit that (1,3-1,4)- β -glucans are not components of cellulose. Since (1,3-1,4)- β -glucanases are not cellulases, Borriss does not disclose each and every element of the claimed invention. Accordingly, Borriss does not anticipate the claims.

As stated above, the Examiner incorrectly asserts that the specification (p. 3, lines 14-25) describe β -1,3-endoglucanase as a cellulose degrading enzyme and states that they’re also called endocellulases. In fact, the recited text in the specification states refers to β -1,4-endoglucanase, not β -1,3-endoglucanase. As Applicants stated in the previous response, β -1,3-endoglucanase are not cellulases. Thus, the reference fails to teach each and every element of the claimed invention.

Applicants therefore respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. § 102(e).

Rejection under 35 U.S.C. § 102: Ryals

Claims 6-9, 11-13, and 18-23 stand rejected under 35 U.S.C. § 102(e) as being anticipated by Ryals *et al.*, U.S. Patent No. 5,614,395, filed January 13, 1994 (“Ryals”).

Applicants respectfully reiterate that Ryals does not disclose a “transgenic plant comprising a nucleic acid encoding a cellulase” and a transgenic seed obtained therefrom, as recited in amended Claims 6-9, 12-13, and 18-23. In particular, for the reasons stated above with respect to Yoshikawa, β -1,3-endoglucanases are not cellulases. As stated previously, the Examiner incorrectly asserts that “the specification (p. 3, lines 14-25) describe β -1,3-endoglucanase as a cellulose degrading enzyme and states that they’re also called endocellulases. The recited text in the specification states

refers to β -1,4-endoglucanase, not β -1,3-endoglucanase. As Applicants stated in the previous response, β -1,3-endoglucanase are not cellulases.

Accordingly, Ryals does not anticipate the claims. Applicants therefore request reconsideration and withdrawal of this rejection under 35 U.S.C. § 102(e).

Rejection under 35 U.S.C. § 103: Bennett

Claims 6-8, 16-18, and 21-23 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Bennett *et al.*, U.S. Patent No. 5,168,064, issued December 1, 1992 (“the ‘064 Patent”).

As stated above, the Examiner incorrectly asserts that the specification (p. 3, lines 14-25) describe β -1,3-endoglucanase as a cellulose degrading enzyme and states that they’re also called endocellulases. In fact, the recited text in the specification states refers to β -1,4-endoglucanase, not β -1,3-endoglucanase. As Applicants stated in the previous response, β -1,3-endoglucanase are not cellulases.

Applicants reiterate that two of the inventors (*i.e.*, Bennett and Lashbrook) of the ‘064 Patent are also authors of the later published Lashbrook reference cited by the Examiner and discussed in detail above. Further, the amino acid sequence of the endo- β -1,4-glucanase disclosed in Table I of the ‘064 Patent is the same sequence later identified in Lashbrook as the endo- β -1,4-glucanase Cel 1 (see Figure 1). Thus, as discussed previously, and by the inventors’ own admission, the endo- β -1,4-glucanase disclosed in the ‘064 Patent is not a cellulase. As the inventors state, “[a]lthough the term ‘cellulase’ has been widely used to describe these endoglucanases, the term is misleading in view of the current lack of evidence for EGase-catalyzed cellulose degradation.” Lashbrook, p. 1486. Further, “the nature of the cell wall substrate(s) modified by these enzymes [*i.e.*, endoglucanases expressed in tomato plants during fruit ripening] and thus their physiological function are unknown.” *Id.* Thus, the reference cited by the Examiner does not teach or suggest all of the claim elements.

For the reasons set forth above, Applicants submit that the ‘064 Patent does not render Claims 6-8, 16-18, and 21-23 obvious. Accordingly, the claims are patentable

over the reference, and Applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C. § 103(a).

Rejection under 35 U.S.C. § 103: Yoshikawa in view of Lao

Claims 6-7, 11-15, and 17-23 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Yoshikawa in view of Lao *et al.* (1991, J. Bacteriol. 173:3397-3407) (“Lao”).

Applicants respectfully submit that, as stated above, the Examiner incorrectly asserts that the specification (p. 3, lines 14-25) describe β -1,3-endoglucanase as a cellulose degrading enzyme and states that they’re also called endocellulases. In fact, the recited text in the specification states refers to β -1,4-endoglucanase, not β -1,3-endoglucanase. As Applicants stated in the previous response, β -1,3-endoglucanase are not cellulases.

For the reasons set forth above and in the previous Response, Applicants submit that Yoshikawa in view of Lao does not render the claims obvious. Accordingly, the claims are patentable over the references cited by the Examiner, and Applicants respectfully request reconsideration and withdrawal of this rejection under 35 U.S.C.


§ 103(a).

CONCLUSION

Pursuant to the foregoing remarks, Applicants respectfully submits that all of the pending claims fully comply with 35 U.S.C. § 112 and are allowable over the prior art of record. Reconsideration of the application and allowance of all pending claims is earnestly solicited. Should the Examiner wish to discuss any of the above in greater detail or deem that further amendments should be made to improve the form of the

claims, then the Examiner is invited to telephone the undersigned at the Examiner's convenience.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Marcia R. Morton", written over a horizontal line.

Marcia R. Morton
Attorney for Applicants
Registration No. 46,942

Syngenta Biotechnology, Inc.
P.O. Box 12257
Research Triangle Park, NC 27709-2257
Telephone: 919-541-8566
September 23, 2003